Trulicity vs Tirzepatide (Mounjaro, Zepbound): 6 Key Differences

Trulicity is not tirzepatide, and it is not semaglutide either. Trulicity is Eli Lilly's brand of dulaglutide, a once-weekly GLP-1 medicine for type 2 diabetes, while tirzepatide is the dual GIP and GLP-1 ingredient in Lilly's Mounjaro and Zepbound. In SURPASS J-mono, a 52-week head-to-head trial, tirzepatide lowered A1C by 2.4 to 2.8 percentage points versus 1.3 for Trulicity 0.75 mg, and people lost 5.8 to 10.7 kg versus 0.5 kg. Only tirzepatide is FDA-approved for weight loss, as Zepbound, and since August 2026 both Mounjaro and Trulicity carry heart-risk indications.

Below you will find six key differences, how the two compare for weight loss, what each costs in November 2026, and what to know about switching.

Quick Answer: Is Trulicity a Tirzepatide or a Semaglutide?

Neither. Trulicity contains dulaglutide, a GLP-1 receptor agonist that acts on one hormone receptor. Tirzepatide (Mounjaro, Zepbound) acts on two, GIP and GLP-1, and semaglutide (Ozempic, Wegovy) is a different GLP-1 drug made by Novo Nordisk. All three are once-weekly injections, but they are different molecules and are not interchangeable.

Which is better depends on why you are asking. For weight loss, tirzepatide is the stronger option and the only one of the two FDA-approved for it. For type 2 diabetes, both are effective weekly injections, and head-to-head data show tirzepatide lowers A1C more.

Trulicity's edge used to be its heart indication. Since August 2026, Mounjaro has one too: in SURPASS-CVOT, tirzepatide was as good as Trulicity at preventing heart attacks, strokes and cardiovascular deaths. Trulicity's indication still covers a broader group, including people with multiple risk factors but no diagnosed heart disease. The right choice depends on your diagnosis, heart history and what your prescriber recommends.

Trulicity vs Tirzepatide at a Glance

Head-to-head figures come from SURPASS J-mono, a 52-week trial in 636 Japanese adults with type 2 diabetes that compared tirzepatide with Trulicity's lowest dose, 0.75 mg. Higher Trulicity doses do better (see below). Weight was a secondary measure in this diabetes trial. Approvals, forms and storage come from the current Trulicity, Mounjaro and Zepbound labels; prices from LillyDirect.

1. They Work on Different Hormones

Trulicity activates one hormone receptor, GLP-1, while tirzepatide activates two, GLP-1 and GIP. Both mimic gut hormones that regulate blood sugar and appetite: they signal the pancreas to release insulin after eating, reduce how much sugar the liver releases, slow stomach emptying and act on appetite centers in the brain. These shared actions explain why both lower blood sugar and reduce hunger.

GIP is a second gut hormone with effects on insulin release, fat tissue and appetite. Engaging both receptors is the leading explanation for why tirzepatide produces larger effects on blood sugar and body weight in clinical trials.

2. They Have Different FDA-Approved Uses

Both are approved for type 2 diabetes and heart-risk reduction, but only tirzepatide is approved for weight loss.

Both Trulicity and Mounjaro are FDA-approved to improve blood sugar in adults and children 10 and older with type 2 diabetes. Both now carry heart-risk indications, with different wording:

• Trulicity is approved to reduce the risk of heart attack, stroke and cardiovascular death in adults with type 2 diabetes who have established heart disease or multiple cardiovascular risk factors. In the REWIND trial of 9,901 adults followed for a median of 5.4 years, Trulicity 1.5 mg lowered that risk compared with placebo (hazard ratio 0.88).
• Mounjaro gained a similar indication in August 2026 for adults with type 2 diabetes at high risk. In SURPASS-CVOT, 13,299 adults with type 2 diabetes and heart or blood vessel disease took tirzepatide or Trulicity 1.5 mg for a median of about four years: 12.2% versus 13.1% had a major event (hazard ratio 0.92). Tirzepatide met the bar for being at least as good as Trulicity but did not prove better.

The distinction most readers care about is weight. Tirzepatide is approved for chronic weight management under the brand name Zepbound, while dulaglutide is not approved for weight loss under any brand. Mounjaro is the diabetes brand of tirzepatide, and prescribing it for weight in someone without type 2 diabetes is off-label.

3. Tirzepatide Produces More Weight Loss

Tirzepatide produces much more weight loss than Trulicity in every comparison available. In SURPASS J-mono, people on tirzepatide lost an average of 5.8 kg, 8.5 kg and 10.7 kg (about 13, 19 and 24 lb, or 7.8% to 13.9% of body weight) at 5, 10 and 15 mg over 52 weeks, while those on Trulicity 0.75 mg lost 0.5 kg (about 1 lb).

That trial used Trulicity's lowest dose. In AWARD-11, a 36-week trial of higher doses, people on Trulicity 4.5 mg lost 4.6 kg (about 10 lb), compared with 3.0 kg on 1.5 mg, according to the Trulicity label. That is more meaningful, but still well below tirzepatide.

Does Trulicity help with weight loss? Modestly. Weight loss is a common effect of the medicine, but it is not FDA-approved for weight management, and its trials were in people with type 2 diabetes.

In dedicated weight-loss trials, tirzepatide's effect is larger still. In SURMOUNT-1, adults without diabetes taking Zepbound lost an average of 15.0%, 19.5% and 20.9% of their body weight at 5, 10 and 15 mg over 72 weeks, compared with 3.1% on placebo. These results are for Zepbound and Mounjaro and have not been shown for compounded tirzepatide.

4. Tirzepatide (Mounjaro) Lowers A1C More

A1C measures average blood sugar over roughly two to three months, and in head-to-head data tirzepatide lowers it more than Trulicity. For people with type 2 diabetes, lowering it is the central treatment goal.

In SURPASS J-mono, tirzepatide lowered A1C by 2.4 to 2.8 percentage points depending on dose, compared with 1.3 points for Trulicity 0.75 mg. The same caveat applies: the trial used Trulicity's starting dose. In AWARD-11, Trulicity's higher doses lowered A1C by up to about 1.8 points at 4.5 mg.

Even allowing for the dose difference, tirzepatide likely keeps its advantage on blood sugar. Individual response varies, and many people on Trulicity reach their A1C targets without a switch. For people not meeting their goals on Trulicity, the evidence suggests tirzepatide offers stronger blood sugar reduction.

5. They Come in Different Doses and Forms

Trulicity comes in four strengths of a single-dose pen, while tirzepatide comes in six strengths and several formats.

Trulicity's prefilled single-dose pens come in 0.75 mg, 1.5 mg, 3 mg and 4.5 mg, each injected once weekly, with the needle built in. Adults start at 0.75 mg and may go to 1.5 mg after four weeks, then up in 1.5 mg steps every four weeks or more, to a maximum of 4.5 mg; children's maximum is 1.5 mg. An unused pen can be kept at room temperature, up to 86°F, for up to 14 days.

Tirzepatide comes in six strengths: 2.5 mg (for starting treatment only), 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg, raised in 2.5 mg steps no faster than every four weeks. It is available as a single-dose pen, a KwikPen holding four weekly doses, and single-dose or multi-dose vials. Single-dose pens and vials can be kept unrefrigerated, up to 86°F, for up to 21 days; the KwikPen and multi-dose vials last 30 days or four doses once opened. Compounded tirzepatide, where prescribed, comes in vials with its own concentration and needs a separate syringe; dose by milligrams with your provider. Our tirzepatide dosage chart explains the steps.

The practical difference: tirzepatide's finer dose ladder gives prescribers more room to slow the increase when side effects appear.

6. Side Effects Are Similar, but Tirzepatide's Can Hit Harder

Both medicines most commonly cause nausea, diarrhea, vomiting, abdominal pain and decreased appetite, and tirzepatide causes them more often.

In SURPASS J-mono, nausea was reported by 12% to 20% of people on tirzepatide, depending on dose, compared with 8% on Trulicity 0.75 mg, and constipation by 14% to 18% versus 11%. In the larger SURPASS-CVOT trial, more stomach and gut side effects were seen with tirzepatide than with Trulicity 1.5 mg. On Trulicity's higher doses in AWARD-11, nausea rose from 13% at 1.5 mg to 16% at 4.5 mg.

Side effects are usually strongest when starting treatment or stepping up a dose and tend to ease over several weeks. Starting low and increasing gradually is the standard approach with both drugs. Tell your provider about side effects that are severe or do not settle.

Trulicity vs Mounjaro vs Zepbound: Cost

As of November 2026, Lilly's self-pay prices are $389 a month for Trulicity, $499 a month for Mounjaro and $299 to $449 per 28 days for Zepbound. All three are made by Eli Lilly and can be bought directly from Lilly with a prescription.

Insurance plans often cover Trulicity and Mounjaro for type 2 diabetes, while coverage of Zepbound for weight loss varies by plan. Supply is no longer the issue it was: as of October 30, 2026, dulaglutide and tirzepatide are not listed in the FDA drug shortage database. For more on coverage, see our guide to weight loss drugs covered by insurance, and for tirzepatide prices across programs, our tirzepatide cost guide.

Compounded tirzepatide is prepared by a licensed pharmacy for one patient's prescription and is not FDA-approved, which means the FDA hasn't reviewed it for safety, effectiveness or quality. It is not Mounjaro or Zepbound and is not covered by insurance.

Tirzepatide vs Trulicity for Weight Loss: Which Should You Choose?

The answer depends on why you are looking at these two drugs.

Weight loss is your goal and you do not have type 2 diabetes. Trulicity is not a realistic option: it is not approved for weight loss and produces far less weight reduction than tirzepatide in every comparison. Zepbound is the approved tirzepatide product in this situation.

You have type 2 diabetes and also want to lose weight. Tirzepatide addresses both goals more strongly. Since August 2026, Mounjaro also has a heart-risk indication, so heart disease is no longer an automatic reason to stay on Trulicity, though Trulicity's indication covers a broader group of people with risk factors.

You are on Trulicity and not meeting your goals. Switching is a legitimate clinical question. That decision belongs with your prescriber, who has your full health picture and medication list.

Can You Switch From Trulicity to Tirzepatide?

Yes, switching from Trulicity to Mounjaro or Zepbound is common, especially for people who are not reaching their A1C or weight goals on Trulicity, given tirzepatide's larger effects in head-to-head trials. It needs your prescriber's guidance.

There is no dose conversion between the two medicines. Even someone on Trulicity 4.5 mg starts tirzepatide at 2.5 mg, the labels' starting dose, and increases no faster than every four weeks. The 2.5 mg dose exists to give your body time to adjust.

Do not take Trulicity and tirzepatide together, and do not stop one and start the other on your own. Both affect blood sugar and insulin, so your prescriber needs to plan the timing and check your other diabetes medicines, especially insulin or a sulfonylurea, which can cause low blood sugar.

Safety Warnings Both Medications Share

Both Trulicity and tirzepatide carry a boxed warning about thyroid C-cell tumors seen in rodent studies; whether this happens in humans is unknown. Neither should be used by anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2).

Both labels also warn about pancreatitis, low blood sugar when combined with insulin or a sulfonylurea, serious allergic reactions, acute kidney injury from dehydration, severe stomach and gut reactions, gallbladder disease, diabetic retinopathy complications in people with a history of retinopathy, and the risk of inhaling stomach contents during anesthesia or deep sedation. Both slow stomach emptying, which can affect how other oral medicines are absorbed.

One tirzepatide-specific warning matters for many readers. Tirzepatide can make birth control pills less effective. The label advises switching to a non-oral method or adding a barrier method for four weeks after starting tirzepatide and for four weeks after each dose increase. Non-oral hormonal birth control is not affected. If you use the pill, discuss this with your prescriber before starting.

How Does Semaglutide Compare?

Semaglutide (Ozempic, Wegovy) is a GLP-1 drug like Trulicity, but it produces more weight loss, and it is approved for weight management under the brand name Wegovy, which Trulicity is not.

On average results, semaglutide sits between Trulicity and tirzepatide. In STEP 1, adults taking Wegovy 2.4 mg lost 14.9% of their body weight over 68 weeks. In SURMOUNT-5, the head-to-head weight trial, adults taking Zepbound lost 20.2% versus 13.7% on semaglutide at Wegovy doses. For the diabetes brands, see our tirzepatide vs Ozempic comparison.

For a lower-cost weekly option, compounded semaglutide through MaxLife costs $89 a month, flat: all-inclusive and the same price at every dose. Like compounded tirzepatide, it is not FDA-approved.

Get Tirzepatide With Medical Guidance

Choosing between GLP-1 options for weight management depends on your health history, what you can tolerate and what a licensed provider decides is appropriate after reviewing your eligibility.

MaxLife is a telehealth platform, not a pharmacy or drug maker. Through MaxLife, an independent licensed provider reviews whether compounded tirzepatide is right for you for adult weight management. The online intake takes about 2 minutes, a provider usually reviews it within 24 hours, and you can ask for a video visit. If you are prescribed treatment, a licensed partner pharmacy prepares and ships it, in all 50 states. The program is for weight management only; keep type 2 diabetes care with the clinician who manages it.

Conclusion

Trulicity is dulaglutide, not tirzepatide or semaglutide. Tirzepatide acts on two receptors instead of one, lowered A1C by 2.4 to 2.8 points versus 1.3 for Trulicity 0.75 mg in a head-to-head trial, and produces substantially more weight loss in every comparison.

Trulicity is not approved for weight loss, while tirzepatide is, as Zepbound. Both now carry heart-risk indications in type 2 diabetes, and in SURPASS-CVOT tirzepatide matched Trulicity on heart outcomes.

Both share a boxed warning for thyroid tumors and similar stomach side effects, though tirzepatide's are more frequent. The right choice belongs with a licensed prescriber.